Relationship of Genetic Variability (HIF‐1Α (rs11549465; P582S), TMPRSS6 (rs855791; V736A) and ABO (rs651007) and Iron Deficiency in Repeated Blood Donors in 2023: A Cross‐Sectional Study Towards Individualized Health Management Authors: Mohammad Pouya Samiee, Azita Chegini, Majid Shahabi, Amir Teimourpour Published: 2026 ABSTRACT ABSTRACTBackground and AimsFrequent blood donation can significantly increase the risk of iron deficiency, influenced by demographic, dietary, environmental, and genetic factors. This study aims to evaluate the association between iron deficiency and specific genetic variations (HIF‐1α (rs11549465; P582S), TMPRSS6 (rs855791; V736A), and ABO (rs651007)) to advance personalized health management strategies.MethodsThis cross‐sectional study was conducted at the Iranian Blood Transfusion Organization (IBTO) between March and September 2023, targeting male donors registered as regular donors in the database (with a minimum of two donations in the past year and at least five donations over the past 3 years) aged 18–65. Strict inclusion criteria were applied to minimize potential confounding variables. To investigate genetic polymorphisms, we utilized techniques such as Sanger sequencing, allele‐specific PCR, and high‐resolution melt (HRM) analysis. Iron status was assessed by measuring key biochemical indicators—serum ferritin, Iron, transferrin saturation (TSAT), and total iron‐binding capacity (TIBC)—through ELISA and colorimetric assays. Statistical analyses were performed using R software (version 4.1.1). Methods included one‐way ANOVA, the Kruskal‐Wallis test, the Shapiro‐Wilk test, and independent samples t‐tests. All tests were two‐sided, with a significance level set at p < 0.05.ResultsThe rs11549465 polymorphism in HIF‐1α was significantly associated with ferritin levels, with the CT genotype group exhibiting higher mean ferritin levels compared to the CC group (p = 0.02; 61.13 ± 42.87 ng/mL vs. 44.60 ± 29.40 ng/mL). No significant associations were observed between rs855791 or rs651007 polymorphisms and biochemical indicators of iron status.ConclusionGenetic screening for the rs11549465 polymorphism could be integrated into donor management programs to personalize strategies for mitigating Iron deficiency risks. Additional research involving larger and more diverse groups is necessary to investigate interactions between genetic, dietary, and environmental factors.Keywords: blood donors, Gene polymorphism, HIF1A, iron deficiency anemia, TMPRSS6 Introduction Iron is an essential micronutrient in human physiology, critical for the synthesis of hemoglobin, myoglobin, and various enzymes involved in cellular metabolism and immune function [1]. Iron deficiency anemia (IDA), the most widespread form of anemia globally, resulting from inadequate iron intake, absorption, or storage. This deficiency impairs oxygen transport, leading to fatigue, reduced cognitive performance, and compromised immune response [2]. Regular blood donors are particularly vulnerable to IDA due to the repeated iron loss through donation [3]. Each donation removes approximately 200–250 mg of iron, and without sufficient replenishment, this can significantly deplete iron stores over time [4, 5]. IDA develops in three progressive stages. Initially, iron stores are depleted due to blood loss exceeding absorption, resulting in lower plasma ferritin and increased iron absorption and transferrin. In the second stage—iron‐deficient erythropoiesis‐ plasma iron and transferrin saturation decline, red cell protoporphyrin rises, and sideroblasts decrease; although anemia may not yet be clinically evident. In the final stage, anemia becomes detectable, initially presenting as normochromic and normocytic, and eventually progressing to microcytic and hypochromic forms [6]. Both iron deficiency without anemia (IDWA) and IDA are common among regular blood donors. Recognizing the risk of iron depletion in this population is essential for implementing evidence‐based prevention strategies and appropriate management [7]. IDWA is a distinct clinical condition that requires timely diagnosis and treatment [8]. Diagnosis typically involves a combination of complete blood count and biochemical markers such as ferritin, transferrin saturation (TSAT), and soluble transferrin receptors (sTfR) [9]. Genetic factors also play a significant role in iron homeostasis and individual susceptibility to IDA [10]. Variants in genes such as HIF‐1α and TMPRSS6 have been extensively studied for their roles in iron regulation [11, 12]. One notable variant is the rs11549465C > T, located in the HIF‐1α gene on chromosome 14. HIF‐1α is a transcription factor that mediates cellular responses to hypoxia and affects iron metabolism by regulating erythropoiesis and iron uptake. The rs11549465 polymorphism results in a proline‐to‐serine substitution at amino acid position 582 (P582S), which may alter protein stability and function. Studies suggest an association between this variant and serum ferritin levels, indicating its potential role in modulating iron storage [13]. Similarly, the rs855791T > C polymorphism in the TMPRSS6 gene on chromosome 22 results in a valine‐to‐alanine substitution at position 736 (V736A). TMPRSS6 encodes matriptase‐2, a key regulator of hepcidin, the hormone that controls intestinal iron absorption and systemic distribution [14]. Variants such as rs855791 in TMPRSS6 have been linked to iron‐refractory IDA due to their impact on hepcidin regulation [11]. Studies on TMPRSS6 shows that certain alleles may either suppress or enhance hepcidin expression, thereby influencing iron metabolism and anemia risk, especially in individuals with frequent iron loss such as regular blood donors [15]. The rs651007T > C polymorphism is located in the ABO gene on chromosome 9, which determines blood group types (A, B, AB, and O) [16, 17]. Emerging evidence suggests that rs651007 may also influence iron metabolism, although the mechanisms remain unclear. Preliminary research shows that this variant could affect cellular iron uptake and distribution by modulating transporter proteins. However, its specific role in regular blood donors is not yet fully understood [18]. This study aims to evaluate the association between iron deficiency in male blood donors and genetic polymorphisms‐ specifically the HIF‐1α rs11549465, TMPRSS6 rs8555791, and ABO rs651007 ‐in order to develop an individualized health management strategy for this population. Materials and Methods Study Design and Participants This cross‐sectional study was conducted at the Tehran Blood Transfusion Center (TBTC) between March and September 2023, targeting regular male blood donors aged 18–65 years. Inclusion criteria were as follows: male donors registered as regular donors in the IBTO database, with a minimum of two donations in the past year and at least five donations over the past 3 years; hemoglobin level ≥ 12.5 g/dL or hematocrit ≥ 38%; body weight over 50 kg; suitable venous access; and negative results in routine screening tests for HIV (antigen/antibody ELISA), hepatitis B surface antigen (HBsAg), hepatitis C virus antigen (HCV‐Ag), and syphilis, in accordance with IBTO protocols. To exclude individuals with systemic inflammation, all participants underwent C‐reactive protein (CRP) testing, and only those with negative results were enrolled. Participants were also required to follow a balanced diet with adequate iron intake. Exclusion criteria included any known medical conditions affecting iron metabolism, such as chronic liver disease, renal disorders, gastrointestinal bleeding, a positive CRP result, or sign and symptoms of active inflammation. In addition to laboratory assessments, all participants completed a structured questionnaire designed to capture dietary and lifestyle factors that may influence iron status. The questionnaire covered dietary habits, smoking history, medication use, and chronic health conditions known to affect iron absorption, metabolism, or loss. Blood samples were collected in two sets: 4 mL in EDTA tubes for DNA analysis and 6 mL in gel clot tubes for serum analysis. Samples were stored at optimal temperatures (2°C–6°C) and processed immediately. Clotted blood samples were centrifuged at 3000 g for 15 min, and the sera were stored at −30°C. Using the G*Power software, and based on a Chi‐square test with 4 degrees of freedom, a significance level of 0.05, 80% statistical power, and a medium effect size (w = 0.3), the minimum sample size was calculated to be approximately 130 participants. DNA Extraction Genomic DNA was extracted from whole blood using an in‐house column‐based DNA extraction method optimized for high‐purity DNA with typical concentrations of 15–25 ng/μL. The extracted DNA was assessed for quality and purity using a NanoDrop spectrophotometer (ND1000, USA), with an A260/A280 ratio of 1.8 or above considered optimal. Sanger Sequencing Following extraction, a total of nine samples were amplified via conventional PCR, and the PCR products were sent to Kodon Gene Company, Iran for sequencing of the HIF‐1α (rs11549465), TMPRSS6 (rs855791), and ABO (rs651007) polymorphisms. Sequencing results were used to validate genotyping and served as reference controls. The primer sequences used for sanger sequencing are listed in Table 1. Table 1The primer sequences used for sanger sequencing.PolymorphismPrimer TypeSequence (5′ → 3′)rs11549465Forward PrimerAGACTTGGAGATGTTAGCTCCCReverse PrimerGCTTTGAGGACTTGCGCTTTrs855791Forward PrimerGAATAGAGAACAGGGGCTCCAReverse PrimerCACCTGACAGGCATCCTTCTrs651007Forward PrimerTTGTCATGGCGATGTGCAAGReverse PrimerGCAGAGCCTTTTATTCCTTCCC The primer sequences used for sanger sequencing. Allele‐Specific PCR (AS‐PCR) AS‐PCR was employed for genotyping rs855791 in TMPRSS6, given its ability to provide clear allele‐specific amplification. Each PCR included controls for both the T and C alleles to confirm specificity. The primer sequences used for allele‐specific PCR are listed in Table 2. Samples were amplified with the following cycling parameters: initial denaturation at 95°C for 5 min, followed by 10 cycles of 95°C for 30 s, annealing starting at 63°C (decreasing by 0.5°C per cycle) for 30 s, and extension at 72°C for 30 s. This was followed by 25 cycles of 95°C for 30 s, 57°C for 30 s, and 72°C for 30 s, ending with a final extension at 72°C for 5 min. PCR products were visualized on 1.5% agarose gel stained with DNA Green Viewer (Pars Tous, Iran), run at 100 V for 50 min, and analyzed under UV light. The primer sequences used for AS‐PCR are listed in Table 2. Table 2Primer sequences.PolymorphismPrimer TypeSequence (5′ → 3′)rs11549465Forward PrimerAGACTTGGAGATGTTAGCTCCCReverse PrimerGCTTTGAGGACTTGCGCTTTrs855791Forward Primer (Allele T)CAGGACCTGTGCAGCGACGTForward Primer (Allele C)CAGGACCTGTGCAGCGAGGCReverse PrimerCACCTGACAGGCATCCTTCTrs651007Forward PrimerTTGTCATGGCGATGTGCAAGReverse PrimerGCAGAGCCTTTTATTCCTTCCC Primer sequences. HRM Assay For the remaining polymorphisms, rs11549465 and rs651007, a High‐Resolution Melt (HRM) analysis was conducted using a Roche LightCycler 96 system. HRM reactions were performed in 15 μL volumes with HRM Master Mix containing DNA polymerase, dNTPs, and EvaGreen dye (Solis Biodyne, Estonia). The sequences of primers utilized for HRM analysis are presented in Table 2. Samples were amplified by denaturation at 95°C for 10 min, followed by 45 cycles of 95°C for 10 s, 60°C for 30 s, and 72°C for 25 s. HRM data were analyzed by plotting fluorescence against temperature, allowing for accurate genotype differentiation based on the unique melting curves of each allele. The primer sequences used for HRM are listed in Table 2. Biochemical Analysis of Iron Status Serum ferritin, iron, and total iron‐binding capacity (TIBC) were measured using commercial kits from Iranian manufacturers. Ferritin concentration was measured via ELISA (Pishtaz Teb, Iran) on a 450 nm ELISA reader, following the manufacturer's instructions. Serum iron was quantified using a Ferrozine‐based colorimetric assay (Delta Darman, Iran) at 570 nm. TIBC was determined using a chromazurol assay on a Hitachi 911 autoanalyzer (Hitachi, Japan). TSAT was calculated using the following formula: Quality Control Measures All assays included duplicate samples and standard controls to ensure reliability. No‐template controls were used in PCR to rule out contamination. Sequencing data validated the accuracy of genotyping methods, and inter‐ and intra‐assay variations for biochemical tests were maintained below 5%. C‐Reactive Protein (CRP) Testing for Inflammation Screening CRP levels were assessed using a latex agglutination assay (Bionik, Iran) to exclude participants with active inflammation, which could affect iron biomarkers. Negative CRP results across all samples confirmed the absence of significant inflammation. Statistical Analysis Data analysis was performed using R software (version 4.1.1). The normality of continuous variables was assessed using the Shapiro–Wilk test. Descriptive statistics were expressed as mean ± standard deviation (SD) for normally distributed data and as median (interquartile range, IQR) for non‐normally distributed data. Categorical variables were presented as counts and percentages. Depending on the data distribution, one‐way ANOVA or the Kruskal–Wallis test was used to compare iron status indicators among genotype groups. Independent‐samples t‐tests and one‐way ANOVAs were used to assess the associations between donors’ age and BMI with genotype, to evaluate their potential confounding effects. All statistical analyses were two‐sided, with an a priori significance level of p < 0.05. All statistical analyses were prespecified according to the study protocol, and no exploratory analyses were performed. Ethical Considerations All participants provided written informed consent, and the study was approved by the Ethics Committee of the High Institute for Research and Education in Transfusion Medicine (Ethical Code: IR.TMI.REC.1401.021). The data was anonymized, kept confidential, and presented in aggregate for research purposes to protect individual privacy. Results Demographic and Baseline Characteristics of Participants The study included 130 regular male blood donors, aged between 21 and 65 years. The mean age of participants was 45 ± 10.5 years, and the average Body Mass Index (BMI) was 28.8 ± 4.1 kg/m2, placing them in the overweight category. Biochemical Indicators of Iron Status in Blood Donors None of the donors had hemoglobin levels below 13.7 g/dL. The mean hemoglobin concentration was 16.55 ± 1.16 g/dL. The average values for the primary iron status indicators were as follows: serum iron (107.29 ± 42.76 µg/dL), ferritin (49.56 ± 34.67 ng/mL), total iron‐binding capacity (TIBC) (289.53 ± 40.61 µg/dL), and TSAT (37.89% ± 15.92%). Of these donors, 10.0% (13/130) had ferritin levels below 12 µg/L, while the remaining 90.0% (117/130) had ferritin levels above 300 µg/L. Regarding iron status, 80.8% (105/130) donors had iron levels above 160 µg/dL, 6.9% (9/130) had values below 50 µg/dL, and 12.3% (16/130) had iron levels more than 160 µg/dL. Among the 13 donors with ferritin < 12 µg/L, 9 had serum iron < 50 µg/dL, and 4 had iron levels > 160 µg/dL. Therefore, 7.0% (9/130) donors had IDWA, and 3.0% (4/130) donors showed negative iron balance. Genotype Distribution and Polymorphism Analysis HRM Assay Results HRM analysis was performed to distinguish genotypes for HIF‐1α (rs11549465) and ABO (rs651007). The HRM curves for each genotype displayed clear, distinct melting profiles, confirming the presence of the CC and CT genotypes for HIF‐1α (rs11549465) and CC, CT, and TT genotypes for ABO (rs651007). This method proved to be efficient and accurate in detecting minor sequence variations between alleles, enabling reliable genotype differentiation within the study population. The HRM results for HIF‐1α (rs11549465) and ABO (rs651007) are shown in Figures 1 and 2, respectively. High‐resolution melting (HRM) analysis of HIF‐1α (rs11549465) polymorphism showing distinct genotyping patterns. (A) Normalized melting curves illustrating separation between genotypes; (B) normalized melting peaks highlighting the specific melting temperatures for each allele. The red curve corresponds to heterozygous C/T, and the blue curve to homozygous C/C. Genotype distribution in the study population was 91 (C/C) and 39 (C/T). High‐resolution melting (HRM) analysis of ABO (rs651007) polymorphism demonstrating clear distinction among genotypes. (A) Normalized melting curves show separation between homozygous C/C (blue), heterozygous C/T (red), and homozygous T/T (orange); (B) normalized melting peaks illustrate characteristic melting temperatures for each genotype. Genotype distribution in the study population was 82 (C/C), 39 (C/T), and 9 (T/T). Allele‐Specific PCR Results AS‐PCR was used to genotype the TMPRSS6 (rs855791) polymorphism. The results identified three distinct genotypes (CC, CT, TT) with clear banding patterns specific to each allele, confirming the accuracy of the AS‐PCR technique in differentiating between alleles. This approach was particularly effective in detecting heterozygous (CT) samples, as it provided clear, allele‐specific amplification. The genotyping results obtained through AS‐PCR were consistent with the sequencing controls used in the study. The results of AS‐PCR analysis for TMPRSS6 (rs855791) are shown in Figure 3. Allele‐specific PCR (AS‐PCR) analysis of TMPRSS6 (rs855791) polymorphism showing distinct banding patterns for each allele. (A) PCR amplification with the C‐specific primer identifies homozygous C/C and heterozygous C/T individuals. (B) PCR amplification with the T‐specific primer distinguishes homozygous T/T and heterozygous C/T individuals. Genotype distribution in the study population was 29 (C/C), 73 (C/T), and 28 (T/T). Three genetic polymorphisms—rs11549465 in HIF‐1α, rs855791 in TMPRSS6, and rs651007 in ABO—were analyzed in this study. Genotype distributions are summarized in Table 3. Table 3Distribution of rs11549465 (HIF‐1α), rs855791 (TMPRSS6) and rs651007 (ABO) genotypes among participants.PolymorphismGenotype N Percentrs11549465C/C9170%C/T3930%T/T00rs855791T/T2821.54%C/T7356.15%C/C2922.31%rs651007T/T96.92%C/T3930.00%C/C8263.08% Distribution of rs11549465 (HIF‐1α), rs855791 (TMPRSS6) and rs651007 (ABO) genotypes among participants. Association Between Genotypes and Iron Indicators Mean values of serum iron, ferritin, TIBC, and TSAT, across different genotypes and polymorphisms are presented in Figure 4. This visual representation highlights the variations in biochemical indicators associated with genetic profiles and suggests the potential role of each genotype in regulating iron metabolism. Heatmap of normalized mean values (0–1 scale) of clinical and biochemical variables (age, BMI, ferritin, iron, TIBC, and TSAT) across genotypes of the studied SNPs (rs11549465, rs651007, and rs855791). Each cell represents the normalized mean of the corresponding variable within a genotype group, allowing direct comparison across variables. Darker colors indicate higher relative values, whereas lighter colors represent lower values. Association Between rs11549465 (HIF‐1Α) and Iron Indicators Analysis revealed a significant association between the rs11549465 polymorphism and ferritin levels, with the CT genotype group showing a higher mean ferritin level compared to the CC group (p = 0.02; 61.13 ± 42.87 ng/mL vs. 44.60 ± 29.40 ng/mL). Table 4 presents a comparison of iron indicators by genotype (CC and CT) for the rs11549465 polymorphism. Table 4Comparison of iron status indicators by rs11549465 genotype.IndicatorGenotype N Mean ± SDMinMax p value* IronC/C91107.08 ± 40.349.71203.850.93C/T39107.76 ± 48.5119.41248.75FerritinC/C9144.60 ± 29.403.45135.14 0.02 C/T3961.13 ± 42.876.60257.10TIBCC/C91294.12 ± 38.38185.00385.000.06C/T39278.82 ± 44.05180.00374.00TSATC/C9137.18 ± 14.672.5279.320.12C/T3939.55 ± 18.626.3997.55*Independent t‐test. Comparison of iron status indicators by rs11549465 genotype. Independent t‐test. Association Between rs855791 (TMPRSS6) and Iron Indicators The rs855791 polymorphism did not show significant associations with any iron status indicators, including serum iron, ferritin, TIBC, or TSAT. These findings suggest that rs855791 may not have a notable impact on iron storage or metabolism in this donor population (Table 5). Table 5Comparison of iron status indicators by rs855791 genotype.IndicatorGenotype N Mean ± SDMinMax p value* IronT/T28101.98 ± 30.3049.75165.020.49C/T73106.25 ± 47.789.71248.75C/C29115.02 ± 39.6819.41203.85FerritinT/T2842.42 ± 29.426.60115.050.36C/T7353.11 ± 31.053.45135.14C/C2947.51 ± 46.235.18257.10TIBCT/T28292.96 ± 41.63181.00374.000.23C/T73284.47 ± 42.12180.00385.00C/C29298.97 ± 34.54215.00381.00TSATT/T2835.72 ± 12.4716.5361.580.71C/T7338.31 ± 17.962.5297.55C/C2938.91 ± 13.496.3965.97*One‐way ANOVA. Comparison of iron status indicators by rs855791 genotype. One‐way ANOVA. Association Between rs651007 (ABO) and Iron Indicators Similar to rs855791, the rs651007 polymorphism showed no significant associations with any measured iron status indicators. Although rs651007 may influence broader aspects of iron metabolism, it does not appear to be directly linked to iron depletion risk in regular donors (Table 6). Table 6Comparison of iron status indicators by rs651007 genotype.IndicatorGenotype N Mean ± SDMinMax p value* IronC/C82109.90 ± 38.0424.27248.750.40C/T39105.79 ± 52.239.71203.98T/T989.98 ± 38.1919.41139.30FerritinC/C8250.34 ± 29.233.45126.670.65C/T3950.29 ± 46.104.35257.10T/T939.27 ± 22.706.6081.79TIBCC/C82285.72 ± 37.46180.00372.000.33C/T39296.31 ± 47.45185.00385.00T/T9294.89 ± 35.79241.00337.00TSATC/C8239.24 ± 14.547.5697.550.25C/T3936.75 ± 19.022.5279.32T/T930.48 ± 11.936.3942.13*One‐way ANOVA. Comparison of iron status indicators by rs651007 genotype. One‐way ANOVA. Evaluation of the Confounding Effects of Donors' Age and BMI We did not observe any significant differences in donors’ age or BMI across different genotypes for any of the studied polymorphisms. Therefore, donors’ age and BMI could not be considered confounding variables in the associations between genotypes and iron status indices (Table 7). Table 7Comparison of donors’ age and BMI across genotypes for rs11549465, rs855791, and rs651007 polymorphisms.VariablePolymorphismGenotype N Mean ± SDMinMax p valueBMIrs11549465C/C9128.74 ± 4.1218.1741.450.90* C/T3928.83 ± 4.0118.9137.22rs855791T/T2827.62 ± 4.6218.9137.220.23** C/T7329.15 ± 3.5821.1337.98C/C2928.92 ± 4.6018.1741.45rs651007C/C8228.62 ± 4.2818.1741.450.77** C/T3929.15 ± 3.7421.1337.98T/T928.44 ± 3.8024.4935.32Agers11549465C/C9146.01 ± 10.2821.0065.000.10* C/T3942.64 ± 10.7623.0062.00rs855791T/T2845.00 ± 10.6726.0061.00> 0.99** C/T7344.93 ± 10.2321.0064.00C/C2945.17 ± 11.3625.0065.00rs651007C/C8245.88 ± 10.6423.0065.000.28** C/T3942.77 ± 10.0121.0059.00T/T946.67 ± 10.9231.0059.00*Independent t‐test.**One‐way ANOVA. Comparison of donors’ age and BMI across genotypes for rs11549465, rs855791, and rs651007 polymorphisms. Independent t‐test. One‐way ANOVA. Discussion Blood donation is crucial for maintaining a stable blood supply, but it can lead to risk of iron depletion, especially in regular donors. Each donation removes about 250 mg of iron, which may result in a negative iron balance [9, 19, 20]. In this study, iron status biomarkers—including serum iron, ferritin, TIBC, and TSAT—showed insufficient levels in 6.9% (9/130), 10% (13/130), 12.3% (16/130), and 13.8% (18/130) of donors, respectively. These findings indicate a notable risk of iron deficiency and anemia among repeated donors, necessitating regular monitoring and management strategies. Iron deficiency rates vary across regions and studies. For example, research in Esfahan, Iran, found low serum iron in 26.6% and low ferritin in 54.4% of repeated male donors [21]. Another Iranian study reported a 28% deficiency rate—higher than our findings [22]. Differences may be due to diet, genetics, or how deficiency is defined. Observed differences may stem from dietary habits, genetic predispositions, or varying definitions of deficiency. In contrast, a Brazilian study showed only 5.5% deficiency among repeated donors [23], while U.S. data reported 8% of male donors with low ferritin [24]. A German study found 26% of regular blood donors had ferritin levels below 15 μg/L, and 12% had iron deficiency anemia [25]. IDWA was more common in young individuals, women, and regular blood donors. A French study of 11,258 whole blood donors found a higher incidence of iron deficiency in women (39.5%) than in men (18%). Among 7200 regular donors, women under 50, new female donors, and regular donors of both sexes showed the highest rates of iron deficiency [26]. In Switzerland, the implementation of routine serum ferritin testing and counseling for donors at risk of donation‐related anemia led to an increase in average hemoglobin (Hb) levels, particularly in women of childbearing age. This intervention significantly reduced both pre‐donation anemia and donor deferrals due to low hemoglobin, demonstrating that systematic ferritin measurements improve the management and prevention of iron deficiency anemia in donors [27]. Denmark uses a similar approach, checking hemoglobin at each donation and ferritin every tenth. Based on results, donors receive iron supplements or advised to extend the interval between donations [28]. These findings highlight the importance of adopting localized approaches tailored to the specific characteristics of each donor population. In addition to demographic and environmental factors, genetic predispositions also play a role in iron metabolism. Carriers of the C/T genotype of rs11549465 showed a significantly higher mean ferritin level (61.13 ± 42.87 ng/mL) compared to other genotypes. HIF‐1α plays a critical role in cellular adaptation to hypoxia, particularly through its regulation of hepcidin, a hormone essential for iron absorption and distribution [29]. This aligns with studies such as Pelucchi et al., which reported enhanced ferritin levels and altered hepcidin expression in T allele carriers, demonstrating the protective effect of this polymorphism in maintaining iron stores during physiological stress [30]. Torti et al. also showed that this polymorphism protects repeated male donors from iron deficiency anemia by maintaining efficient iron homeostasis during physiological stress [13]. These findings suggest rs11549465 could be a useful genetic marker for identifying donors less prone to iron depletion. The rs855791 polymorphism in the TMPRSS6 gene, which encodes matriptase‐2, has been widely studied for its role in regulating hepcidin expression [14]. Although no significant associations were identified in this study, previous research has highlighted its relevance. For instance, Sørensen et al. demonstrated that the T allele of rs855791 is associated with lower ferritin levels, particularly in women, while Mast et al. reported similar findings in independent cohorts [31, 32, 33]. Moreover, genome‐wide association studies (GWAS) have also linked this SNP to reduced serum iron, transferrin saturation, and hemoglobin levels, especially among individuals with low dietary iron intake [34]. The absence of a significant effect in our sample may reflect population‐specific genetic variation. The rs651007 polymorphism, though less explored, has been implicated in iron distribution through interactions with transporter proteins. Benyamin et al. reported a strong association between this variant and reduced ferritin levels in European populations [18]. These findings subsequently confirmed by Raffield et al [35]. McLachlan and colleagues further observed, in a cohort of 11,093 Europeans, that rs651007 correlates with both decreased ferritin concentrations and a lower risk of atherosclerosis [36]. In our study, however, we detected no significant associations, a discrepancy that may arise from the low minor allele frequency or limited statistical power. Larger sample sizes and applying advanced statistical models could clarify the role of rs651007 in systemic iron regulation. Collectively, these results highlight the complex interplay of genetic, environmental, and demographic factors in iron metabolism among blood donors. The variability in polymorphism effects across studies underscores the necessity of region‐specific donor management guidelines that integrate both genetic and local environmental factors. The association between rs11549465 and ferritin levels in our and other studies suggests a promising opportunity to incorporate targeted genetic screening into donor care. Personalized approaches, such as adjusted donation intervals or genotype‐guided iron supplementation, could significantly reduce the risk of iron deficiency anemia and improve donor health and retention. Limitations and Further Research To reduce gender‐related variability and eliminate potential confounding factors such as hormonal fluctuations, menstrual cycles, and pregnancy‐related changes in iron status, only male donors were included [37]. This approach is further supported by demographic data indicating that over 96% of blood donors in Tehran are male [38]. This study's cross‐sectional design, small male‐only sample, and the absence of precise donation frequency data limit causal inference and generalizability. Future research should adopt longitudinal methodologies, employ objective biochemical and genetic measurements, and recruit a larger, gender‐balanced cohort with comprehensive donation records. Examining how varying donation intervals and volumes influence hematological parameters and long‐term health outcomes—underpinned by standardized data collection and rigorous statistical analysis—would provide deeper insights. The absence of the TT genotype for HIF‐1α (rs11549465) in our sample presents an additional tis another limitation, likely due to the T allele's low frequency (3‐10%) in different populations (population‐based data (gnomAD, 1000 Genomes, TOPMed), genetic drift or population‐specific allele frequency distribution, resulting in an expected TT frequency of less than 1–2% under Hardy–Weinberg equilibrium. To strengthen and extend these conclusions, future large‐scale, multi‐center, longitudinal studies are warranted. Integrating environmental exposures, detailed dietary and lifestyle data, comprehensive genotyping, and epigenetic profiling will advance our understanding of iron homeostasis. Ultimately, these efforts could inform genotype‐based strategies to optimize donor health and ensure sustainable blood supply. Conclusion This study identifies the rs11549465 polymorphism in HIF‐1α as a marker associated with improved iron storage in regular blood donors. In contrast, no significant associations were observed for rs855791 (TMPRSS6) and rs651007 (ABO) polymorphisms. These results suggest that genetic screening could optimize donor management strategies to mitigate iron deficiency risks. Future research in larger, diverse cohorts is needed to confirm these results and explore the interactions between genetic, dietary, and environmental factors. Author Contributions Mohammad Pouya Samiee, Azita Chegini, Majid Shahabi: conceptualization, writing – original draft. Mohammad Pouya Samiee, Amir Teimourpour: data curation, methodology. Azita Chegini, Majid Shahabi: validation. Azita Chegini, Majid Shahabi, Amir Teimourpour: investigation. Azita Chegini, Majid Shahabi: supervision, visualization. Azita Chegini: writing – review and editing. Mohammad Pouya Samiee: funding acquisition. Ethics Statement This study was approved by the Ethics Committee of the High Institute of Education and Research in Transfusion Medicine (ethics code: IR.TMI.REC.1401.021). Conflicts of Interest The authors declare no conflicts of interest. This study was conducted without any financial support. All authors have read and approved the final version of the manuscript. Dr Azita Chegini had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis. Transparency Statement The lead author, Mohammad Pouya Samiee, affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. Acknowledgments Mohammad Pouya Samiee, Azita Chegini, Majid Shahabi, and Amir Teimourpour were responsible for the design of the study and data analysis. Mohammad Pouya Samiee, Azita Chegini, and Amir Teimourpour were responsible for data analysis, writing, and final content. All authors have read and approved this manuscript. Azita Chegini had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis. The present study did not receive any financial support. As such, no funding sources or financial relationships influenced the study design; collection, analysis, or interpretation of data; writing of the report; or the decision to submit. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. Data is available from the corresponding author upon request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. Data is available from the corresponding author upon request.